CANCER type

Disease type

  • BUILDING ON A ROBUST PRECLINICAL FOUNDATION

    Our preclinical research has already demonstrated remarkable results, showing that our NIK degraders can:

    Suppress tumor growth

    Overcome treatment resistance

    Fire up the tumor microenvironment

  • NEXT MILESTONE: CLINICAL TRIALS

    We're preparing to advance our first-in-class NIK-targeted therapy into clinical trials, bringing hope to patients not responding to current treatments.

  • STATUS AND NEXT STEPS

    We are working on establishing proof of concept with multiple early-stage assets, with the goal of identifying a lead candidate for development.

BUILDING ON A ROBUST PRECLINICAL FOUNDATION

Our preclinical research has already demonstrated remarkable results, showing that our NIK degraders can:

  • Suppress tumor growth

  • Overcome treatment resistance

  • Fire up the tumor microenvironment

NEXT MILESTONE: CLINICAL TRIALS

We're preparing to advance our first-in-class NIK-targeted therapy into clinical trials, bringing hope to patients not responding to current treatments.

STATUS AND NEXT STEPS

We are working on establishing proof of concept with multiple early-stage assets, with the goal of identifying a lead candidate for development.